169353 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors Neurotransmitters
Sub-classes:DETECTING AND DIFFERENTIATING NEUROTRANSMITTERS USING ULTRAVIOLET PLASMONIC-ENGINEERED NATIVE FLUORESCENCE
#2Pregabalin Immunoassays
#3RAPID ON-SITE DETECTION METHOD FOR GAMMA-HYDROXYBUTYRIC ACID
#4PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS)
#5BIOSENSORS FOR DETECTING CHANGES IN THE LEVEL OF A NEUROTRANSMITTER IN THE CENTRAL NERVOUS SYSTEM
#6NOVEL BENZOXAZOLE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF TO DETECT GHB IN DRINKS AND URINE
#7Sensors for Aromatic Compounds and Methods of Making and Using Same
#8RNA APTAMER THAT SPECIFICALLY BINDS HISTAMINE
#9Methods and kits for the derivatization of a biogenic amine
#10TREATMENT AND DIAGNOSIS OF CHRONIC INFLAMMATORY CONDITIONS IN THE LOWER URINARY TRACT
#11Method for simultaneous analysis of neurotransmitters and their metabolites based on derivatization
#12SAMPLING METHOD AND KIT FOR HISTAMINE MEASUREMENT
#13Pregabalin immunoassays
#14Imaging neurotransmitters in vivo using functionalized carbon nanotubes
#15METHOD FOR TREATING INTESTINAL GLUTAMINE SYNTHETASE ACTIVITY DEFICIENCY
#16Biosensor for multi-analyte characterization
#17PHARMACEUTICAL COMPOSITION FOR INDUCING EXERCISE MIMETIC EFFECT
#18MEASURING METHOD AND MEASURING DEVICE
#19Antibodies to quetiapine and use thereof
#20Antibodies to paliperidone and use thereof
#21Methods of treating phenylketonuria
#22Antibodies to paliperidone haptens and use thereof
#23DETERMINING MELATONIN LEVEL IN A BIOLOGICAL SAMPLE
#24SYSTEM AND METHOD FOR DETECTION OF A CONTAMINATED BEVERAGE
#25Imaging Neurotransmitters In Vivo Using Functionalized Carbon Nanotubes
#26Methods and kits for the derivatization of a biogenic amine
#27Biosensor for multi-analyte characterization
#28Pregabalin immunoassays
#29Compositions and methods for improved neurotoxin assays
#30DEVICE FOR ONLINE MEASUREMENT OF NEUROTRANSMITTERS USING ENZYMATIC REACTORS
#31Metal oxide-based biocompatible hybrid sorbent for the extraction and enrichment of catecholamine neurotransmitters and related compounds, and method of synthesis
#32Resonance energy transfer assay with cleavage sequence and spacer
#33Antibodies to quetiapine and use thereof
#34System and method for detection of a contaminated beverage
#35Antibodies to paliperidone haptens and use thereof
#36Near-infrared fluorescent sensors for biological amines
#37METHODS FOR MANAGING CARE OF PATIENTS PREDISPOSED TO PROGRESSIVE MITRAL VALVE DISEASES
#38Antibodies to paliperidone and use thereof
#39Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles
#40Pregabalin immunoassays
#41Resonance energy transfer assay with cleavage sequence and spacer
#42System and method for detection of a contaminated beverage
#43Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors
#44METHODS FOR ASSESSING VAGINAL ATROPHY
#45Treatment of inflammation using alpha 7 receptor-binding agonists
#46Resonance energy transfer assay with cleavage sequence and spacer
#47Device for online measurement of neurotransmitters using enzymatic reactors
#48Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
#49System and method for detection of a contaminated beverage
#50NANOSCALE COAXIAL ELECTRODE ARRAYS AND METHODS THEREOF
#51Antibodies to paliperidone and use thereof
#52Resonance energy transfer assay with cleavage sequence and spacer
#53Preparing hapten-specific antibodies and their application for immunodiagnostics and research
#54Apparatus and procedure for in vitro measurement of a substance, nicotine, released from a smokeless tobacco product
#55METHOD FOR ASSAYING PROTEIN-PROTEIN INTERACTION
#56p16 MEDIATED REGULATION OF NMDA RECEPTORS
#57NMDAR biomarkers for diagnosis and treatment of traumatic brain injury and other disorders
#58Neurotransmitter sensors and methods of using the same
#59Drug-Enhanced Neurofeedback
#60TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING AGONISTS
#61Methods for detecting catecholamines by mass spectrometry
#62Fluorescent substrates for neurotransmitter transporters
#63Personalized drug treatment and smoking cessation kit and method
#64TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS
#65Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
#66NOVEL METHOD FOR SCREENING BRAIN-ACTIVE COMPOUNDS
#67Methods and system for the identification and characterization of peptides and their functional relationships by use of measures of correlation
#68Resonance energy transfer assay with cleavage sequence and spacer
#69Method for measuring neurotransmitters in vivo
#70Methods of Identifying Improved NMDA Receptor Antagonists
#71TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS
#72Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease
#73p16 MEDIATED REGULATION OF NMDA RECEPTORS
#74Methods for detecting catecholamines by mass spectrometry
#75C-terminal domain truncation of mGluR1α by calpain and uses thereof
#76Nicotinic desensitizers and methods of selecting, testing, and using them
#77CHEMICAL MESSENGER SENSOR
#78METHODS, COMPOSITIONS AND USES THEREOF
#79METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES
#80Method of diagnosing neuropsychiatric diseases, eating disorders or metabolic diseases
#81METHODS OF DIAGNOSIS AND TREATMENT OF EQUINE LAMINITIS AND CUSHING'S SYNDROME
#82NMDAR Biomarkers for Diagnosis and Treatment of Traumatic Brain Injury and Other Disorders
#83Drug development target protein and target gene, and method of screening
#84ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY
#85Tropane compounds
#86Methods for diagnosing cerebrovascular events based on NR2 peptides
#87Modified amino acids, pharmaceuticals containing these compounds and method for their production
#88Biosensor having nano wire for detecting food additive mono sodium glutamate and manufacturing method thereof
#89BIOSENSOR HAVING NANO WIRE AND MANUFACTURING METHOD THEREOF
#90MOLECULES INVOLVED IN SYNAPTOGENESIS AND USES THEREFOR
#91Treatment of inflammation using α7 receptor-binding cholinergic agonists
#92Method of quantifying the G protein-coupled receptor (GPCR)/G protein coupling using a cell membrane array
#93System and method for using platelet biomarkers for diagnosis and treatment of neuro-psychiatric conditions
#94Method for identifying compounds which affect synaptogenesis
#95Polypeptide and the use thereof
#96Fluorescent substrates for neurotransmitter transporters
#97ASSAYS
#98Neurotransmitter sensors and methods of using the same
#99Receptor ligands and methods of modulating receptors
#100Ubiquitination of Membrane Transporters
#101Method for quantitative and semi-quantitative detection of l-phenylalanine, l-tyrosine, l-3,4-dihydroxyphenylalanine and their corresponding keto-acids, phenylpiruvic acid, 3-hydroxyphenylpyruvic acid and 3,4-dihydroxyphenylpyruvic acid in biological fluids, related kits for diagnosis and monitoring of altered metabolisms of these aminoacids
#102Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
#103Identification of therapeutic compounds
#104Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
#105Methods for diagnosing and treating cerebrovascular events based on NR2 peptides
#106Methods for identifying cell surface receptor protein modulators
#107Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
#108Clinical assay for monitoring of agmatine
#109β2-adrenergic receptor agonists
#110Antibody assay methods to assess risk for TIA/stroke
#111Assay methods for immediate diagnosis of cause of stroke
#112Methods and compositions for treatment of central nervous system disorders
#113Method for assaying protein-protein interaction
#114Glutamate transport modulatory compounds and methods
#115Neuroprotective therapeutics preventing ERK/MAPK activation through the NMDA receptor
#116Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
#117Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
#118Interaction of NMDA receptor with protein tyrosine phosphatase
#119Constitutively active histamine H3 receptor mutants and uses thereof
#120Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
#121β2-adrenergic receptor agonists
#122Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
#123Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
#124Treating neuropathic pain with neuropeptide FF receptor 2 agonists
#125Interaction of NMDA receptor with protein tyrosine phosphatase
#126Method for assaying protein—protein interaction
#127Modified tachykinin receptors
#128Interaction of NMDA receptor with protein serine threonine phosphatases
#129Monitoring circadian activity
#130Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors